ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials

March 25, 2011

CTRC, UCLA Receive Gifts; NCCF Distributes Gold Pins.

March 24, 2000

USPSTF Delivers “D” Recommendation For Ovarian Cancer Screening

September 28, 2012

Wisconsin Group Takes Lead In Challenging Pain Control Perception

April 21, 1989

ASCO Recommends Against Routine Adjuvant Chemo For Stage II Colon Cancer

August 27, 2004

Grand Jury Clears Eppley, Shubik

October 24, 1980